Navidea Biopharmaceuticals to Present at 2nd Annual NASH Summit
April 16 2018 - 7:01AM
Business Wire
Navidea Biopharmaceuticals (NYSE MKT: NAVB) (“Navidea” or “the
Company”), a company focused on the development of precision
immunodiagnostic agents and immunotherapeutics, today
announced it will present at the 2nd Annual NASH Summit in Boston,
MA being held April 23-25, 2018. Michael Goldberg, President and
Chief Executive Officer, will be giving a new presentation focused
on Navidea’s NASH research; the presentation will be available on
Navidea’s website following the conference.
Event: 2nd Annual NASH ConferencePresentation
Date: Wednesday, April 25thPresentation Time: 11:30am
ESTLocation: Revere Hotel Boston Common, Boston, MA
To schedule a meeting with Navidea management at the conference,
please contact Navidea Investor Relations at
tpatel@edisongroup.com.
About NavideaNavidea Biopharmaceuticals, Inc. (NYSE
American: NAVB) is a biopharmaceutical company focused on the
development of precision immunodiagnostic agents and
immunotherapeutics. Navidea is developing multiple
precision-targeted products based on its Manocept™ platform to
enhance patient care by identifying the sites and pathways of
disease and enable better diagnostic accuracy, clinical
decision-making, and targeted treatment. Navidea’s Manocept
platform is predicated on the ability to specifically target the
CD206 mannose receptor expressed on activated macrophages. The
Manocept platform serves as the molecular backbone of Tc 99m
tilmanocept, the first product developed and commercialized by
Navidea based on the platform. The development activities of the
Manocept immunotherapeutic platform are being conducted by Navidea
in conjunction with its subsidiary, Macrophage Therapeutics, Inc.
Navidea’s strategy is to deliver superior growth and shareholder
return by bringing to market novel products and advancing the
Company’s pipeline through global partnering and commercialization
efforts.
For more information, please visit www.navidea.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180416005587/en/
Navidea Biopharmaceuticals, Inc.Jed Latkin,
614-551-3416CFO/COOjlatkin@navidea.comorEdison AdvisorsTirth Patel,
646-653-7035Vice President, Investor
Relationstpatel@edisongroup.com
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Apr 2023 to Apr 2024